Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q2 2026 · 10-Q
Revenue$187.55K$187.55Kno prior Q2 2025 on file Net Income-$2.98M-$2.98MN/M vs Q2 2025 EPS Diluted-$0.20-$0.20N/M vs Q2 2025 Operating Income-$2,967,980N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,855,632N/M Margins · derivedOperating margin-1582.5%
Net margin-1590.4%
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end